The Liver Meeting, The 62nd Annual Meeting of the American Association for the Study of Liver Diseases

November 4-8, 2011 - San Francisco

AASLD 2011: Upping Ribavirin Dose Does Not Increase Interferon Effectiveness in HIV/HCV Coinfected Patients

Starting hepatitis C treatment with a double dose of ribavirin plus erythropoietin to manage anemia did not lead to higher rates of sustained response to interferon-based therapy in HIV/HCV coinfected people, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this month in San Francisco.alt

Read more:

AASLD 2011: HCV Screening of 1945-1965 Birth Cohort Appears Cost-Effective

Screening all people in the U.S. in the 46 to 66 year age group for hepatitis C virus (HCV) infection would identify more than 800,000 additional cases, and offering testing plus treatment if needed would be cost-effective, according to an analysis presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this month in San Francisco.alt

Read more:

AASLD 2011: High Sustained Response Rates with PSI-7977 Plus Pegylated Interferon/Ribavirin

Adding the hepatitis C virus (HCV) polymerase inhibitor PSI-7977 to pegylated interferon plus ribavirin produced a 91% cure rate for previously untreated patients with hard-to-treat HCV genotype 1, according to results from the PROTON study presented this month at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.alt

Read more:

AASLD 2011: Good Response to Entecavir Reduces Risk of Hepatitis B Liver Disease Progression

Chronic hepatitis B patients who achieve HBV DNA viral load suppression on entecavir (Baraclude) have a lower risk of liver failure, hepatocellular carcinoma, and death than non-responders, according to study findings presented this month at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.alt

Read more:

AASLD 2011: Epidemic of Sexually Transmitted HCV among HIV+ Gay Men in Amsterdam Levels Off

The epidemic of apparently sexually transmitted hepatitis C virus (HCV) infection among HIV positive men who have sex with men (MSM) in Amsterdam appears to have stabilized since 2008-2009, but monitoring and prevention efforts are still needed, according to data presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) last week in San Francisco.alt

Read more: